Gritstone Bio Comprehensive Income 2017-2024 | GRTSQ
Gritstone Bio comprehensive income from 2017 to 2024. Comprehensive income can be defined as the change in net assets of a business enterprise during a period from transactions and other events and circumstances from nonowner sources. It includes all changes in equity during a period except those resulting from investments by owners and distributions to owners.
Gritstone Bio Annual Comprehensive Income (Millions of US $) |
2023 |
$0 |
2022 |
$-0 |
2021 |
$-0 |
2020 |
$ |
2019 |
$0 |
2018 |
$-0 |
2017 |
$-0 |
2016 |
$-0 |
Gritstone Bio Quarterly Comprehensive Income (Millions of US $) |
2024-06-30 |
$-0 |
2024-03-31 |
$-0 |
2023-12-31 |
$0 |
2023-09-30 |
$-0 |
2023-06-30 |
$-0 |
2023-03-31 |
$-0 |
2022-12-31 |
$-0 |
2022-09-30 |
$-0 |
2022-06-30 |
$-0 |
2022-03-31 |
$-0 |
2021-12-31 |
$-0 |
2021-09-30 |
$0 |
2021-06-30 |
$0 |
2021-03-31 |
$-0 |
2020-12-31 |
|
2020-09-30 |
$0 |
2020-06-30 |
$0 |
2020-03-31 |
$-0 |
2019-12-31 |
$0 |
2019-09-30 |
$0 |
2019-06-30 |
$0 |
2019-03-31 |
$0 |
2018-12-31 |
$-0 |
2018-09-30 |
$-0 |
2018-06-30 |
|
2018-03-31 |
|
2017-12-31 |
|
2017-09-30 |
|
2016-12-31 |
|
Sector |
Industry |
Market Cap |
Revenue |
Medical |
MED-BIOMED/GENE |
$0.000B |
$0.016B |
Gritstone Oncology is developing tumor-specific cancer immunotherapies to fight multiple cancer types. The company has built its tumor-specific immunotherapy approach on two key pillars - first, a proprietary machine learning-based platform, Gritstone EDGE(TM), which provides a powerful ability to predict from a routine tumor biopsy the tumor-specific neoantigens, or TSNA, that are presented on a patient?s tumor cells; and second, the ability to develop and manufacture potent immunotherapies utilizing patients? TSNA to drive the patient?s immune system to attack and destroy tumors.
|